Log in

NASDAQ:FENCFennec Pharmaceuticals Stock Price, Forecast & News

$7.40
+0.08 (+1.09 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$7.25
Now: $7.40
$7.49
50-Day Range
$6.32
MA: $7.03
$7.58
52-Week Range
$3.26
Now: $7.40
$8.40
Volume29,439 shs
Average Volume129,703 shs
Market Capitalization$187.66 million
P/E RatioN/A
Dividend YieldN/A
Beta0.18
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.
Read More
Fennec Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.00 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FENC
CUSIPN/A
Phone919-636-4530

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.33 per share

Profitability

Net Income$-12,770,000.00

Miscellaneous

EmployeesN/A
Market Cap$187.66 million
Next Earnings Date8/14/2020 (Estimated)
OptionableOptionable

Receive FENC News and Ratings via Email

Sign-up to receive the latest news and ratings for FENC and its competitors with MarketBeat's FREE daily newsletter.

Fennec Pharmaceuticals (NASDAQ:FENC) Frequently Asked Questions

How has Fennec Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Fennec Pharmaceuticals' stock was trading at $6.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, FENC stock has increased by 11.6% and is now trading at $7.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Fennec Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fennec Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Fennec Pharmaceuticals.

When is Fennec Pharmaceuticals' next earnings date?

Fennec Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, August 14th 2020. View our earnings forecast for Fennec Pharmaceuticals.

How were Fennec Pharmaceuticals' earnings last quarter?

Fennec Pharmaceuticals Inc (NASDAQ:FENC) released its quarterly earnings results on Thursday, May, 14th. The company reported ($0.19) earnings per share for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.19). View Fennec Pharmaceuticals' earnings history.

What price target have analysts set for FENC?

1 brokerages have issued 12-month target prices for Fennec Pharmaceuticals' stock. Their forecasts range from $15.00 to $15.00. On average, they expect Fennec Pharmaceuticals' stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 102.7% from the stock's current price. View analysts' price targets for Fennec Pharmaceuticals.

Has Fennec Pharmaceuticals been receiving favorable news coverage?

News headlines about FENC stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Fennec Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutFennec Pharmaceuticals.

Are investors shorting Fennec Pharmaceuticals?

Fennec Pharmaceuticals saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 691,100 shares, a drop of 19.0% from the April 15th total of 852,900 shares. Based on an average trading volume of 68,200 shares, the short-interest ratio is currently 10.1 days. Approximately 4.2% of the shares of the stock are sold short. View Fennec Pharmaceuticals' Current Options Chain.

Who are some of Fennec Pharmaceuticals' key competitors?

What other stocks do shareholders of Fennec Pharmaceuticals own?

Who are Fennec Pharmaceuticals' key executives?

Fennec Pharmaceuticals' management team includes the following people:
  • Mr. Rostislav Raykov, Pres, CEO & Director (Age 42)
  • Mr. Robert C. Andrade, Chief Financial Officer (Age 43)
  • Mr. Mark Gowland, Controller
  • Mr. Lei Fang, Pres of Pharstat Inc
  • Ms. Anne McKay, Regulatory Consultant (Age 64)

What is Fennec Pharmaceuticals' stock symbol?

Fennec Pharmaceuticals trades on the NASDAQ under the ticker symbol "FENC."

Who are Fennec Pharmaceuticals' major shareholders?

Fennec Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Granahan Investment Management Inc. MA (1.09%), Cadence Capital Management LLC (0.74%), Hartford Financial Management Inc. (0.21%), Victory Capital Management Inc. (0.04%) and Victory Capital Management Inc. (0.05%). View institutional ownership trends for Fennec Pharmaceuticals.

Which major investors are selling Fennec Pharmaceuticals stock?

FENC stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA. View insider buying and selling activity for Fennec Pharmaceuticals.

Which major investors are buying Fennec Pharmaceuticals stock?

FENC stock was purchased by a variety of institutional investors in the last quarter, including Cadence Capital Management LLC, Hartford Financial Management Inc., Victory Capital Management Inc., and Victory Capital Management Inc.. View insider buying and selling activity for Fennec Pharmaceuticals.

How do I buy shares of Fennec Pharmaceuticals?

Shares of FENC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Fennec Pharmaceuticals' stock price today?

One share of FENC stock can currently be purchased for approximately $7.40.

How big of a company is Fennec Pharmaceuticals?

Fennec Pharmaceuticals has a market capitalization of $187.66 million. The company earns $-12,770,000.00 in net income (profit) each year or ($0.64) on an earnings per share basis.

What is Fennec Pharmaceuticals' official website?

The official website for Fennec Pharmaceuticals is www.fennecpharma.com.

How can I contact Fennec Pharmaceuticals?

Fennec Pharmaceuticals' mailing address is PO BOX 13628 68 TW ALEXANDER DRIVE, DURHAM NC, 27709. The company can be reached via phone at 919-636-4530.

This page was last updated on 5/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.